FGFBP2 and breast carcinoma: To this end, we completed multiplex immunohistochemistry (mIHC) on primary tumour tissues from 6 non-metastatic early breast cancer (EBC) and 4 metastatic breast cancer (MBC) patients to determine the relative proportion of FGFBP2+ γδ T cells between these two conditions.